Download PDF
Horm Metab Res 2001; 33(10): 612-617
DOI: 10.1055/s-2001-17909
Original Clinical
© Georg Thieme Verlag Stuttgart · New York

Triglyceride-Rich Lipoprotein Cholesterol Exceeds Low-Density Lipoprotein Cholesterol in Hypertriglyceridemia Patients

M. Ai1 , A. Tanaka1 , N. Tomie1 , K. Ogita2 , M. Sekine2 , F. Numano2 , F. Numano1
  • 1 Third Department of Internal Medicine, Tokyo Medical and Dental University, Tokyo, Japan
  • 2 Department of Internal Medicine, Tokyo Metropolitan Kiyose Hospital, Tokyo, Japan
Further Information

Publication History

Publication Date:
18 October 2001 (online)

Also available at
    Permissions and Reprints

The atherogenicity of triglyceride-rich lipoprotein has been revealed. This study was performed to explore the clinical importance of triglyceride-rich lipoprotein by measuring its cholesterol content and comparing it with other lipoprotein fractions. Blood samples were obtained from 103 patients whose fasting plasma triglyceride concentration exceeded 300 mg/dl. The cholesterol monitor using the technique of high-performance liquid chromatography was used for the measurement of their plasma cholesterol concentrations and the determination of cholesterol distribution among lipoprotein fractions. This monitor showed 4 peaks: large-triglyceride-rich lipoprotein, small-triglyceride-rich lipoprotein, low-density lipoprotein, and high-density lipoprotein. Total cholesterol increased with increasing triglyceride. The increment of total cholesterol was nearly equal to that of small-triglyceride-rich lipoprotein cholesterol. Small-triglyceride-rich lipoprotein cholesterol exceeded low-density lipoprotein cholesterol where plasma triglyceride concentration was over 500 mg/dl. In conclusion, triglyceride-rich lipoprotein may be clinically important for hypertriglyceridemic patients as a source of cholesteryl ester in arteriosclerotic plaques, and increased triglyceride-rich lipoprotein cholesterol may be used as a basis for hypertriglyceridemia atherogenicity. Our study suggests that hypertriglyceridemia should be treated to prevent arteriosclerotic disease.

Key words:

Triglyceride - Hypercholesterolemia - Hypertriglyceridemia - Triglyceride-Rich Lipoprotein - Arteriosclerosis - Apolipoprotein

References

  • 1 Bradley W A, Brown M L, Ramprasad M P, Li R, Song R, Gianturco S H. Antipeptide antibodies reveal interrelationships of MBP 200 and MBP 235: unique apoB-specific receptors for triglyceride-rich lipoproteins on human monocyte-macrophages.  J Lipid Res. 1999;  40 744-752
    PubMedGoogle Scholar
  • 2 Gianturco S H, Ramprasad M P, Song R, Li R, Brown M L, Bradley W A. Apolipoprotein B-48 or its apolipoprotein B-100 equivalent mediates the binding of triglyceride-rich lipoproteins to their unique human monocyte-macrophage receptor.  Atherioscler Thromb Vasc Biol. 1998;  18 968-976
    PubMedGoogle Scholar
  • 3 Matthew L, Brown M L, Ramprasad M P, Umeda P K, Tanaka A, Kobayashi Y, Watanabe T, Shimoyamada H, Kuo W L, Li R, Song R, Bradley W A, Gianturco S H. A macrophage receptor for apolipoprotein B48: Cloning, expression, and atherosclerosis.  Proc Natl Acad Sci USA. 2000;  97 7488-7493
    CrossrefPubMedGoogle Scholar
  • 4 Anderson K M, Castelli W P, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study.  JAMA. 1987;  257 2176-2180
    CrossrefPubMedGoogle Scholar
  • 5 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).  Lancet. 1994;  344 1383-1389
    PubMedGoogle Scholar
  • 6 Shepherd J, Cobbe S M, Ford I, Isles C G, Lorimer A R, Macfarlane P W, McKillop J H, Packard C J, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.  N Engl J Med. 1995;  333 1301-1307
    CrossrefPubMedGoogle Scholar
  • 7 Manninen V, Tenkanen L, Koskinen P, Huttunen J K, Manttari M, Heinonen O P, Frick M H. Joint effects of serum triglyceride and LDL cholesterol concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study.  Circulation. 1992;  85 37-45
    CrossrefPubMedGoogle Scholar
  • 8 Sniderman A D, Wolfson C, Teng B, Franklin F A, Bachorik P S, Kwiterovich P O Jr. Association of hyperapobeta lipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis.  Ann Intern Med. 1982;  97 833-839
    PubMedGoogle Scholar
  • 9 Hulley S B, Rosenman R H, Bawol R D, Brand R J. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart disease.  N Engl J Med. 1980;  302 1383-1389
    CrossrefPubMedGoogle Scholar
  • 10 Bradley W A, Booyse F M, Gianturco S H. Fibrinolytic and thrombotic factors in atherosclerosis and IHD: the influence of triglyceride rich lipoproteins (TGRLP).  Atherosclerosis. 1994;  108 (Suppl.) S31-S39
    CrossrefPubMedGoogle Scholar
  • 11 Austin M A. Plasma triglyceride and coronary heart disease.  Arterioscler Thromb. 1990;  11 2-14
    PubMedGoogle Scholar
  • 12 Hokanson J E, and Austin M A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.  J Cardiovasc Risk. 1996;  3 213-219
    CrossrefPubMedGoogle Scholar
  • 13 Hodis H N, Mack W J. Triglyceride rich lipoproteins and the progression of coronary artery disease.  Curr Opin Lipidol. 1995;  6 209-214
    PubMedGoogle Scholar
  • 14 Falk E. Why do plaques rupture?.  Circulation. 1992;  86 (Suppl. III) 30-40
    PubMedGoogle Scholar
  • 15 Mizuno K, Arai T, Satomura K, Shibuya T, Arakawa K, Okamoto Y, Miyamoto A, Kurita A, Kikuchi M, Nakamura H, Utsumi A, Takeuchi K. New percutaneous transluminal coronary angioscopy.  J Am Coll Cardiol. 1989;  13 353
    PubMedGoogle Scholar
  • 16 deFeyter P J, Ozaki Y, Baptista J, Escaned J, Mario C D, de Jaegere P PT, Serruys P W, Roelandt J RTC. Ischemia-related lesion characteristics in patients with stable or unstable angina. A study with intracoronary angioscopy and ultrasound.  Circulation. 1995;  92 1408-1413
    PubMedGoogle Scholar
  • 17 Ross R. The pathogenesis of atherosclerosis. A perspective for the 1990s.  Nature. 1993;  362 801-809
    CrossrefPubMedGoogle Scholar
  • 18 Okazaki M, Sasamoto K, Muramatsu T, Hosaki S. Analysis of plasma lipoproteins by gel permeation chromatography.  Handbook of lipoprotein testing. In: Rifai N, Warnick GR, Dominiczak MH (eds). Washington, DC:; AACC press, 1997: 531-548
    Google Scholar
  • 19 Allain C C, Poon L S, Chan C S, Richmond W, Fu P C. Enzymatic determination of total resum cholesterol.  Clin Chem. 1974;  20 470-475
    PubMedGoogle Scholar
  • 20 Wahlfield A W. Triglyceride determination after enzymatic hydrolysis. In: Bergmeyer HU (ed). Methods of enzymatic analysis.  New York:; Academic, 1974: 1831-1835
    Google Scholar
  • 21 Kitahara M, Shinomiya M, Shirai K, Saito Y, Yoshida S. Frequency and role of apo E phenotype in familial hypercholesterolemia and non-familial hyperlipidemia in the Japanese.  Atherosclerosis. 1990;  82 197-204
    PubMedGoogle Scholar
  • 22 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus.  Diabetes Care. 1998;  21 (Suppl. 1) S5-S19
    PubMedGoogle Scholar
  • 23 Campos E, Nakajima K, Tanaka A, Havel R J. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100.  J Lipid Res. 1992;  33 369-380
    PubMedGoogle Scholar
  • 24 Milne R W, Weech P K, Blanchette L, Davignon J, Alaupovic P, Marcel Y L. Isolation and characterization of apolipoprotein B-48 and B-100 very low density lipoproteins from type III hyperlipoproteinemic subjects.  J Clin Invest. 1984;  73 816-823
    PubMedGoogle Scholar
  • 25 Minnich A, Nordestgaard B G, Zilversmit D B. A novel explanation for the reduced LDL cholesterol in severe hypertriglyceridemia.  J Lipid Res. 1989;  30 347-355
    PubMedGoogle Scholar
  • 26 Havel R J, Gordon R S Jr. Idiopathic hyperlipidemia: metabolic studies in an affected family.  J Clin Invest. 1960;  39 1777-1790
    PubMedGoogle Scholar

Akira Tanaka, M.D.

Third Department of Internal Medicine
Tokyo Medical and Dental University

1-5-45, Yushima, Bunkyo-ku
Tokyo 113-8519
Japan


Phone: + 81 (3) 5803-5228

Fax: + 81 (3) 5803-5228

Email: tanaka.med3@tmd.ac.jp

      >